IP Library Granted Patent US 8,722,853
Granted Patent B2
US 8,722,853 · App. 13/158,246 · Granted May 13, 2014

Methods and systems for adenovirus interaction with desmoglein 2 (DSG2)

Inventors: Andre Lieber (Seattle, WA); Hongjie Wang (Seattle, WA)
Assignee: University of Washington through its Center for Commercialization
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,722,853
App. No.
13/158,246
Granted
May 13, 2014
Kind
B2
Abstract

The present invention provides compositions, compounds, and methods relating to recombinant adenoviral-based polypeptides for treating disorders associated with epithelial tissues.

Claims (27)

1. A recombinant polypeptide, comprising:

(a) one or more fiber polypeptide shaft domains, wherein the one or more polypeptide shaft domains each comprise an amino acid sequence according to SEQ ID NO:11;

(b) a fiber polypeptide knob domain, operatively linked to and located C-terminal to the one or more polypeptide knob domains, wherein the polypeptide knob domain comprises an amino acid sequence according to SEQ ID NO:13; and

(c) one or more non dimerization domains operatively linked to and located N-terminal to the one or more polypeptide shaft domains.

2. The recombinant polypeptide of claim 1 , wherein the polypeptide does not include an adenoviral polypeptide tail domain.

3. The recombinant polypeptide of claim 1 , wherein the one or more shaft domains comprise 1-22 shaft domains.

4. The recombinant polypeptide of claim 1 , wherein each shaft domain comprises an amino acid sequence according to SEQ ID NO 12: GVLTLKCLTPLTTTGGSLQLKVGGGLT(V/I)DDTDG(T/F)L(Q/K)ENI(G/S)ATTPLVKTGHSIGL(S/P)LG(A/P)GLGT(D/N)ENKLC(T/A)KLG(E/Q)GLTFNSNNICI(D/N)DNINTL.

5. The recombinant polypeptide of claim 1 , wherein each shaft domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5.

6. The recombinant polypeptide of claim 1 , wherein the knob domain comprises an amino acid sequence according to SEQ ID NO 14: WTGVNPT(E/R)ANCQ(M/I)(M/I)(D/N/A)SSESNDCKLILTLVKTGALVTAFVYVIGVSN(N/D)FNMLTT(Y/H)(R/K)NINFTAELFFDS(A/T)GNLLT(S/R)LSSLKTPLNHKSGQNMATGA(I/L)TNAK(S/G)FMPSTTAYPFN(N/D/V)NSRE(--/K)(-/E)NYIYGTC(H/Y)YTASD(H/R)TAFPIDISVMLN(Q/R)RA(I/L)(R/N)(A/D/N)(D/E)TSYCIR(IN)TWSWNTG(DN)APE(GN)QTSATTLVTSPFTFYYIREDD.

7. The recombinant polypeptide of claim 1 , wherein the knob domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10.

8. The recombinant polypeptide of claim 1 , wherein the dimerization domain comprises an amino acid sequence selected from the group consisting of EVSALEK (SEQ ID NO:22) and/or KVSALKE (SEQ ID NO: 23).

9. The recombinant polypeptide of claim 1 , wherein the recombinant polypeptide comprises:

(a) one or more shaft domains that each comprise an Ad3 shaft domain (SEQ ID NO:1); and

(b) a knob domain that comprises an Ad3 knob domain (SEQ ID NO:6).

10. The recombinant polypeptide of claim 9 , comprising the amino acid sequence of junction opener-1 (JO-1) (SEQ ID NO:20).

11. The recombinant polypeptide of claim 1 , wherein the polypeptide contains a single polypeptide shaft domain.

12. The recombinant polypeptide of claim 1 , wherein the polypeptide is multimerized.

13. The recombinant polypeptide of claim 1 , wherein the polypeptide is dimerized.

14. The recombinant polypeptide of claim 1 , further comprising one or more compounds conjugated to the recombinant polypeptide.

15. The recombinant polypeptide of claim 14 , wherein the one or more compounds are selected from the group consisting of therapeutics, diagnostics, and imaging agents.

16. The recombinant polypeptide of claim 15 , wherein the one or more compounds comprise at least one therapeutic, wherein the therapeutic is selected from the group consisting of antibodies, immunoconjugates, nanoparticles, chemotherapeutics, radioactive particles, viruses, vaccines, cellular immunotherapy therapeutics, gene therapy constructs, nucleic acid therapeutics, and combinations thereof.

17. A pharmaceutical composition, comprising

(a) the recombinant polypeptide of claim 1 ; and

(b) a pharmaceutically acceptable carrier.

18. The pharmaceutical composition of claim 17 , wherein the recombinant polypeptide is multimerized.

19. The pharmaceutical composition of claim 17 , wherein the recombinant polypeptide comprises a dimer of the polypeptide of SEQ ID NO:20.

20. The pharmaceutical composition of claim 17 , further comprising an amount of one or more therapeutics sufficient to treat a disorder associated with epithelial tissue, a diagnostic sufficient to diagnose a disorder associated with epithelial tissue, and/or an imaging agent sufficient to image an epithelial tissue.

Assignments (3)
CONFIRMATORY LICENSE Recorded Nov 12, 2014
From: UNIVERSITY OF WASHINGTON / CENTER FOR COMMERCIALIZATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 034207/0345 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2011
From: LIEBER, ANDRE; WANG, HONGJIE
To: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Reel/Frame 026674/0496 →
CONFIRMATORY LICENSE Recorded Jul 7, 2011
From: UNIVERSITY OF WASHINGTON/CENTER FOR COMMERCIALIZATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026553/0569 →
Continuity (4)
Provisional Application 61353652 · Jun 10, 2010
Provisional Application 61430091 · Jan 5, 2011
Provisional Application 61470663 · Apr 1, 2011
Related Publication 20110305634A1 · Dec 15, 2011